PDS Biotechnology Corp
corporate_fare Company Profile
PDS Biotechnology Corp (NASDAQ:PDSB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for PDSB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for PDSB spans PRE 14A, 8-K, S-3, SCHEDULE 13D.
Recent high-impact activity:
- PDS Biotech Seeks 1-for-10 to 1-for-35 Reverse Split to Hold Nasdaq Listing
- PDS Biotech Posts Q3 Loss of $7.6M With $15.2M Cash and Zero Long-Term Debt
- NantWorks Exercises PDS Biotech Warrants for $3.9M in Gross Proceeds
- PDS Biotech Swaps Four Directors for Three Pharma Veterans, Leaves One Seat Open
- PDS Biotech Registers 110M Shares for Resale, Including 50M Milestone Warrants
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 3,523,357 shares in PDSB as of the October 30, 2026 settlement, a 4.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 40.0% of PDSB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PDSB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.
$50 Million At-The-Market (ATM) Offering Activated · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →